Introduction
============

Approximately 12.7 million cancer cases were newly diagnosed and 7.6 million people died of cancer each year worldwide.[@b1-ott-9-087] As a complex multi-step disease, cancer is strongly affected by various genetic and environmental factors, of which gene polymorphism is an essential cause for the different genetic susceptibility to cancer.[@b2-ott-9-087] Identification of the potential genetic markers is important for screening, early diagnosing and predicting the occurrence of cancer.

Osteopontin (OPN), alternatively known as secreted phosphoprotein 1 (SPP1), is involved in a series of physiological and pathophysiological processes including cell attachment, proliferation, migration, invasion, tissue remodeling, bone formation, and inflammation.[@b3-ott-9-087] As a member of the SIBLING (small integrin-binding ligand N-linked glycoproteins) family that includes five members of secreted proteins, OPN can modulate cell behavior by both autocrine and paracrine mechanisms interacting with cell surface receptors such as integrins.[@b4-ott-9-087] OPN has been reported to be expressed within tumor cells as well as in the surrounding stroma of multiple human cancers, providing a relation with malignant invasion.[@b5-ott-9-087] Additionally, it has been shown that OPN is frequently overexpressed in numerous cancers and contributes to the formation and progression of tumor.[@b6-ott-9-087] Considering the potential role of OPN in the initiation and development of cancer, much attention has been paid to the relation of OPN with various types of cancers.

Human *OPN* gene is located on chromosome 4q21-q25 and spans approximately 11 kb, consisting of seven exons and six introns. Sequence variation especially the polymorphic site changing the binding activity of certain transcription factor in promoter region hold great promise in altering the regulation of the gene's transcription and thereby modulating cancer risk.[@b7-ott-9-087] In recent years, an increasing number of studies investigated the association between polymorphisms of *OPN* gene promoter region and risk of cancer.[@b8-ott-9-087]--[@b16-ott-9-087] The most commonly studied *OPN* promoter polymorphisms included rs28357094 (-66G/T), rs17524488 (-156-/G), and rs11730582 (-443C/T). However, the results from individual studies were inconclusive.

Individual study possessed insufficient power to obtain a comprehensive and reliable conclusion due to limited sample size and ethnicities. Until now, no meta-analysis has been performed to explore the relation of *OPN* gene promoter polymorphisms with risk of cancer. In order to provide insights into the role of promoter polymorphisms of *OPN* gene in carcinogenesis, we perform a meta-analysis on the association between three most frequently studied *OPN* promoter polymorphisms (rs28357094 G/T, rs17524488 -/G, and rs11730582 C/T) and cancer risk.

Materials and methods
=====================

Identification and eligibility of relevant studies
--------------------------------------------------

Literatures of electronic databases including PubMed, Web of Science, and Chinese National Knowledge Infrastructure were systematically searched using different combinations of the search terms including "*OPN/SPP1*", "polymorphism/mutation/variant", and "cancer/neoplasm/malignancy". References cited in each identified literatures were further searched manually for potential available studies. When overlapping data exists, only the largest and latest study was selected. We contacted the author for specific raw data if the data provided in the article were not sufficient. The last search date was October 5, 2014.

Inclusion and exclusion criteria
--------------------------------

Studies included in this meta-analysis must meet the inclusion criteria as follows: case-control studies investigating the association between *OPN* gene promoter polymorphisms (rs28357094, rs17524488, and rs11730582) and risk of cancer; studies with sufficient raw data for assessing odds ratios (ORs) and their 95% confidence interval (CI); studies published in English or Chinese. Exclusion criteria were no relevance; reviews or letters; animal experiments for OPN; functional studies of OPN; duplicate publications; and not for rs17524488 or rs11730582 polymorphisms of OPN.

Data extraction
---------------

Two authors (Jingwei Liu and Caiyun He) independently extracted the data from the included studies. The following information was extracted from each study: name of first author, year of publication, ethnicity of the population, type of studied cancer, the source of the control group, numbers of cases and controls, and genotyping methods of *OPN* polymorphism. The conflict was resolved after discussion, and consensus was finally reached on all of the extracted information.

Statistical analysis
--------------------

The statistical analysis was performed by Stata software (Version 11.0; StataCorp, College Station, TX, USA). ORs and their 95% CI were applied to assess the strength of association between *OPN* gene polymorphisms and cancer risks. A *P*-value of \<0.05 was considered as statistically significant. Heterogeneity was assessed by using Q statistic (*P*\<0.10 indicates significant heterogeneity between studies) and I-squared (*I*^2^) value.[@b17-ott-9-087] A fixed-effects model using Mantel--Haenszel method[@b18-ott-9-087] was performed to calculate the pooled ORs when heterogeneity between studies was not significant. Otherwise, a random-effects model using DerSimonian and Laird method[@b19-ott-9-087] was used. Sensitivity analysis was carried out to explore heterogeneity when significant heterogeneity was indicated. Meta-regression was further conducted to investigate the source of heterogeneity. The between-studies variance (τ[@b2-ott-9-087]) was used to quantify the degree of heterogeneity between studies, and the percentage of τ[@b2-ott-9-087] was adopted to describe the extent of heterogeneity explained.[@b20-ott-9-087] Subgroup analyses were performed to explore the effects of genotyping methods and source of controls. In addition, publication bias was evaluated by Begg's test[@b21-ott-9-087] and Egger's test,[@b22-ott-9-087] respectively. *P*-value \<0.05 for Begg's and Egger's tests suggests significant publication bias.

Results
=======

Characteristics of the included studies
---------------------------------------

This meta-analysis was organized according to the PRISMA statement ([Table S1](#SD3-ott-9-087){ref-type="supplementary-material"}). A total of 423 potentially relevant literatures were initially indentified through electronic databases after duplicates removal. After carefully reviewing the titles and abstracts of these articles, 398 records were excluded due to no relevance, reviews or letters, and animal experiments. The remaining 25 full-text articles were further assessed for eligibility. Finally, nine articles were included in the present meta-analysis.[@b8-ott-9-087]--[@b16-ott-9-087] The detailed flow chart of article selection was shown in [Figure 1](#f1-ott-9-087){ref-type="fig"}.

The main characteristics of the studies included in this meta-analysis were summarized in [Table 1](#t1-ott-9-087){ref-type="table"}. No discrepancy was found between the two authors who performed the data extraction. All the included case-control studies were published in English or Chinese. The ethnicities of the studied populations were all Asians. Seven articles including 2,136 cases and 2,655 controls investigated the association between rs17524488 (-156-/G) polymorphism and risk of cancer;[@b9-ott-9-087],[@b11-ott-9-087]--[@b16-ott-9-087] nine studies explored the relation of rs11730582 (-443C/T) polymorphism with risk of cancer.[@b8-ott-9-087]--[@b16-ott-9-087] The types of cancers studied in relation to *OPN* promoter polymorphisms included gastric cancer, thyroid cancer, lung cancer, cervical cancer, oral cancer, glioma, and liver cancer. The genotyping methods of *OPN* promoter polymorphisms included sequencing, Taqman, and polymerase chain reaction/ligase detection reaction.

For *OPN* promoter polymorphism rs28357094 (-66G/T), seven articles were included. It is worth noting that four of these studies[@b9-ott-9-087],[@b11-ott-9-087],[@b12-ott-9-087],[@b14-ott-9-087] did not find any individuals with GG or GT genotypes and all the cases and controls were TT genotype, which preclude us from further analyzing the data as the number of the study sample was very limited. Only two articles[@b15-ott-9-087],[@b16-ott-9-087] observed three different genotypes (GG, GT, and TT) and the genotyping method for them were both Taqman. Therefore, it still requires further research that whether the genotyping method had an impact on the results because sequencing and polymerase chain reaction/ligase detection reaction methods did not find any genetic variants of this polymorphism. The detailed information of the studies concerning the relation of *OPN* promoter polymorphism rs28357094 (-66G/T), and the risk of cancer was summarized in [Table S1](#SD3-ott-9-087){ref-type="supplementary-material"}.

Association of OPN rs17524488 (-156-/G) polymorphism with cancer risk
---------------------------------------------------------------------

Results of the association between *OPN* rs17524488 (-156-/G) polymorphism and cancer risk was summarized in [Table 2](#t2-ott-9-087){ref-type="table"}. Carriers of GG genotype were observed to be significantly associated with increased risk of cancer compared with wild-type -/- carriers (OR =1.40, 95% CI =1.03--1.91, *P*=0.033, [Figure 2](#f2-ott-9-087){ref-type="fig"}). Individuals with -/G genotype were significantly associated with increased risk of cancer compared with wild-type -/- genotype (OR =1.22, 95% CI =1.07--1.40, *P*=0.002, [Figure 3](#f3-ott-9-087){ref-type="fig"}). In addition, G allele was also significantly associated with increased risk of cancer compared with (-) allele (OR =1.21, 95% CI =1.04--1.40, *P*=0.016, [Figure S1](#SD1-ott-9-087){ref-type="supplementary-material"}).

Subgroup analysis was performed to explore the effect of different genotyping methods and source of controls. For subgroup of sequencing method, *OPN* rs17524488 (-156-/G) polymorphism was consistently associated with increased risk of cancer in all compared genetic models (GG vs -/-: OR =1.41, 95% CI =1.07--1.87, *P*=0.016; -/G vs GG: OR =1.32, 95% CI =1.06--1.65, *P*=0.012; G allele vs (-) allele: OR =1.23, 95% CI =1.07--1.42, *P*=0.004). For subgroup of Taqman method, however, no significant association was found in any of the compared genetic models. Besides, hospital-based subgroup demonstrated significant association of rs17524488 polymorphism with increased risk of cancer while no such association was observed in population-based subgroup.

Association of OPN rs11730582 (-443C/T) polymorphism with cancer risk
---------------------------------------------------------------------

Results of the association between *OPN* rs11730582 (-443C/T) polymorphism and cancer risk was summarized in [Table 3](#t3-ott-9-087){ref-type="table"}. Carriers of CC or CT genotype were not significantly associated with altered risk of cancer compared with wild-type TT genotype (CC vs TT: OR =0.98, 95% CI =0.49--1.97, *P*=0.964, [Figure 3A](#f3-ott-9-087){ref-type="fig"}; CT vs TT: OR =0.88, 95% CI =0.54--1.43, *P*=0.610, [Figure 3B](#f3-ott-9-087){ref-type="fig"}). As for allele analysis, we did not observed any significant association of *OPN* rs11730582 (-443C/T) polymorphism and altered cancer risk (C allele vs T allele: OR =0.92, 95% CI =0.64--1.33, *P*=0.665, [Figure S2](#SD2-ott-9-087){ref-type="supplementary-material"}). Additionally, subgroup analyses based on genotyping method and source of controls also did not demonstrate any significant association between *OPN* rs11730582 polymorphism and risk of cancer.

Heterogeneity test, sensitivity analysis, and meta-regression
-------------------------------------------------------------

In most comparisons of *OPN* rs11730582 (-443C/T) polymorphism and several comparisons of *OPN* rs17524488 (-156-/G) polymorphism, significant heterogeneity was observed. Subgroup analysis could not fully eliminate the heterogeneity. We subsequently performed sensitivity analysis to investigate the influence of individual study on the pooled estimate by omitting one study from the pooled analysis each time. The results indicated that no individual study significantly affected the pooled OR (figure not shown), suggesting that the outcomes of the meta-analysis were robust.

Meta-regression was therefore conducted to explore the source of the heterogeneity in the association between *OPN* rs11730582 (-443C/T) polymorphism and risk of cancer. The results of meta-regression suggested that none of the factors including cancer type (*P*=0.168), control source (*P*=0.800), and genotyping method (*P*=0.350) significantly contributed to the source of heterogeneity for CC vs TT comparison. For CT vs TT comparison, none of cancer type (*P*=0.429), control source (*P*=0.756), and genotyping method (*P*=0.792) significantly contributed to the source of heterogeneity.

Publication bias
----------------

The Begg's test and Egger's test were performed to quantitatively assess the publication bias of the included studies. The detailed information for publication bias test was shown in [Table 4](#t4-ott-9-087){ref-type="table"}. For both the associations of *OPN* rs17524488 (-156-/G) polymorphism and *OPN* rs11730582 (-443C/T) polymorphism with cancer risk, no significant publication bias was observed in the present meta-analysis.

Discussion
==========

Previous individual studies concerning the associations between *OPN* promoter polymorphisms and cancer risk came up with inconsistent results. This meta-analysis investigated the role of *OPN* promoter polymorphisms (rs28357094 G/T, rs17524488 -/G, and rs11730582 C/T) in carcinogenesis. Through analyzing the data extracted from previous full-text publications, we revealed that *OPN* rs17524488 (-156-/G) polymorphism was significantly associated with increased cancer risk, but no significant association was observed of *OPN* rs11730582 (-443C/T) polymorphism with altered risk of cancer. Additionally, the frequency of G allele of rs28357094 (-66G/T) polymorphism was very low that no further analysis was performed.

Osteopontin, first detected in 1979, is a secreted phosphorylated protein expressed in a variety of tissues as well as bodily fluids with cell-adhesive and chemotactic properties.[@b23-ott-9-087] Osteopontin contains several functional domains such as calcium-binding domain, RGD (arginine--glycine--aspartic acid) sequence and thrombin cleavage site, which is important for binding to integrins and CD44.[@b24-ott-9-087] OPN is initially known to display several functions in different physiological and pathological processes, including cell-mediated immunity, bone remodeling, maintenance or reconfiguration of tissue integrity during inflammatory processes.[@b25-ott-9-087] Subsequently, it has been reported that OPN was overexpressed in various kinds of cancers including gastric, colon, renal, pancreatic, lung, and prostate cancers.[@b26-ott-9-087] The expression of OPN in different cell types was significantly influenced by its genetic polymorphisms of the promoter.[@b27-ott-9-087] Considering the potential role of OPN in carcinogenesis, much attention has recently been paid to the relation of *OPN* promoter polymorphism (rs28357094 G/T, rs17524488 -/G, and rs11730582 C/T) and risk of cancer, but the results were inconclusive.

In this meta-analysis, we revealed that carriers of GG or -/G genotype of *OPN* promoter rs17524488 (-156-/G) polymorphism were significantly associated with increased risk of cancer compared with wild-type -/- carriers, respectively (GG vs -/-: OR =1.40, *P*=0.033; -/G vs GG: OR =1.22, *P*=0.002). As for allele analysis, G allele was significantly associated with increased risk of cancer compared with (-) allele (OR =1.21, *P*=0.016). Subgroup of sequencing demonstrated that *OPN* rs17524488 (-156-/G) polymorphism was consistently associated with increased risk of cancer in all compared genetic models (GG vs -/-: OR =1.41; -/G vs GG: OR =1.32; G allele vs (-) allele: OR =1.23). However, no such significant association was observed in any compared genetic models for subgroup of Taqman method, which indicated that the genotyping method may have an impact on the relation of this polymorphism and cancer risk. Additionally, hospital-based subgroup demonstrated significant association of rs17524488 polymorphism with increased risk of cancer while no significant association was found in population-based subgroup, suggesting that the source of controls adopted might influence the association of this polymorphism with cancer risk. For *OPN* rs11730582 (-443C/T) polymorphism, no significant association was observed with risk of cancer in any of the genetic models (CC vs TT: OR =0.98, *P*=0.964; CT vs TT: OR =0.88, *P*=0.610; C allele vs T allele: OR =0.92, *P*=0.665). Besides, subgroup analysis also did not reveal any significant association.

Emerging evidence has suggested that OPN has an important role in tumorigenesis.[@b28-ott-9-087],[@b29-ott-9-087] It has been reported that polymorphisms in the *OPN* gene promoter can affect its transcriptional activity and rs17524488 (-156-/G) polymorphism is located at the binding site of transcriptional factor RUNX2.[@b30-ott-9-087],[@b31-ott-9-087] Reporter gene expression experiments with the *OPN* promoter polymorphisms revealed that the sequence variants G-insertion at position 155 in combination with the 66T allele resulted in a significantly increased reporter gene expression.[@b30-ott-9-087] Additionally, RUNX2 factor was shown to bind better to the G allele than to the (-) allele of rs17524488 (-156-/G) polymorphism.[@b30-ott-9-087] As a result, the rs17524488 (-/G) polymorphism located at promoter region (-156) of *OPN* gene might influence the binding affinity of transcriptional factors and promoter activity, thereby altering OPN expression. Individual genotypes of the *OPN* promoter rs17524488 (-/G) polymorphism might display different regulatory efficiencies by transcription factors including RUNX2, resulting in diverse susceptibilities for cancer. Although the above-mentioned studies might partly account for the observed significant association between *OPN* promoter rs17524488 (-156-/G) polymorphism and increased risk of cancer, future functional and mechanism investigations are still warranted. In addition, we were aware that a meta-analysis by Liu et al[@b32-ott-9-087] also investigated the association of OPN polymorphism and risk of cancer. But the present study had certain differences: First, the previous meta-analysis only focused on Chinese population while our meta-analysis included all available ethnicities, which could increase the applicability of the results. Second, we also search database of Chinese National Knowledge Infrastructure for literatures published in Chinese and further unpublished data. Furthermore, we performed allele analysis of OPN promoter polymorphisms and subgroup analysis based on different genotyping methods to explore more available results. Further large-scale and well-designed investigations are still required to confirm the results of our meta-analysis.

Several limitations should be acknowledged in the present meta-analysis. First, the studied sample was relatively not large enough especially for certain subgroup analysis. Second, obvious heterogeneity was observed in the comparisons of *OPN* promoter rs11730582 (-443C/T) polymorphism and risk of cancer, which could not be fully explained by subgroup analysis and meta-regression. Third, the ethnicities of all the included studies were Asians, which inevitably limited the generalizability of our conclusion. Fourth, other important raw data such as age, sex, and family history were not available for each individual study so that we could not obtain results with adjustments by other co-variables. Fifth, the combination of the data from different types of cancers and different sequencing methods may lead to the population heterogeneous and decreased the power of the study.

Conclusion
==========

In summary, this meta-analysis indicated that carriers of GG or -/G genotype of *OPN* promoter rs17524488 (-156-/G) polymorphism might be associated with increased risk of cancer compared with wild-type -/- carriers, respectively. However, no significant association was observed between *OPN* promoter rs11730582 (-443C/T) polymorphism and risk of cancer. Further large-scale and well-designed investigations concerning different ethnicities are still required to confirm the results of our meta-analysis.

Supplementary materials
=======================

PRISMA checklist
----------------

###### 

Forest plot for the association between *OPN* rs17524488 (-156-/G) polymorphism and cancer risk (G allele vs - allele).

**Note:** Weights are from random-effects analysis.

**Abbreviations:** OPN, osteopontin; OR, odds ratio; CI, confidence interval.

###### 

Forest plot for the association between *OPN* rs11730582 (-443C/T) polymorphism and cancer risk (C allele vs T allele).

**Note:** Weights are from random-effects analysis.

**Abbreviations:** OPN, osteopontin; OR, odds ratio; CI, confidence interval.

###### 

Information of studies concerning the relation of *OPN* promoter polymorphism rs28357094 (-66G/T) and risk of cancer

  Author                       Year   Ethnicity   Cancer type       Controls source   Case   Control   Genotyping method                     
  ---------------------------- ------ ----------- ----------------- ----------------- ------ --------- ------------------- ----- ----- ----- ------------
  Mu et al[@b33-ott-9-087]     2013   Chinese     Thyroid cancer    PB                97     167       99                  108   191   114   Taqman
  Lee et al[@b34-ott-9-087]    2013   Chinese     Gastric cancer    HB                0      0         146                 0     0     128   Sequencing
  Chen et al[@b35-ott-9-087]   2013   Chinese     Lung cancer       PB                0      4         356                 0     9     351   Sequencing
  Zhao et al[@b36-ott-9-087]   2012   Chinese     Gastric cancer    PB                0      0         200                 0     0     200   Sequencing
  Xu et al[@b37-ott-9-087]     2011   Chinese     Cervical cancer   PB                113    90        97                  235   358   181   Taqman
  Chiu et al[@b38-ott-9-087]   2010   Chinese     Oral cancer       NA                0      0         97                  0     0     100   Sequencing
  Chen et al[@b39-ott-9-087]   2010   Chinese     Glioma            HB                0      0         670                 0     0     680   PCR-LDR

**Abbreviations:** OPN, osteopontin; PB, population-based; HB, hospital-based; NA, not applicable; PCR-LDR, polymerase chain reaction/ligase detection reaction.
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![Forest plots for the association between *OPN* rs17524488 (-156-/G) polymorphism and cancer risk.\
**Notes:** (**A**) Forest plot for the association between *OPN* rs17524488 (-156-/G) polymorphism and cancer risk (GG vs -/-); (**B**) Forest plot for the association between *OPN* rs17524488 (-156-/G) polymorphism and cancer risk (-G vs -/-). Weights are from random-effects analysis.\
**Abbreviations:** OPN, osteopontin; OR, odds ratio; CI, confidence interval.](ott-9-087Fig2){#f2-ott-9-087}

![Forest plots for the association between *OPN* rs11730582 (-443C/T) polymorphism and cancer risk.\
**Notes:** (**A**) Forest plot for the association between *OPN* rs11730582 (-443C/T) polymorphism and cancer risk (CC vs TT); (**B**) Forest plot for the association between *OPN* rs11730582 (-443C/T) polymorphism and cancer risk (CT vs TT). Weights are from random-effects analysis.\
**Abbreviations:** OPN, osteopontin; OR, odds ratio; CI, confidence interval.](ott-9-087Fig3){#f3-ott-9-087}

###### 

Characteristics of the included studies in this meta-analysis

  Author                                                                  Year   Ethnicity   Cancer type       Controls source   Case   Control   Genotyping method                                 
  ----------------------------------------------------------------------- ------ ----------- ----------------- ----------------- ------ --------- ------------------- ----- ----- ----- ----- ----- ------------
  **rs17524488/rs11439060 (-156-/G)**                                                                                                                                                               
  Mu et al[@b15-ott-9-087]                                                2013   Chinese     Thyroid cancer    PB                363    72        187                 104   413   94    219   100   Taqman
  Lee et al[@b14-ott-9-087]                                               2013   Chinese     Gastric cancer    HB                146    26        72                  48    128   18    64    46    Sequencing
  Chen et al[@b13-ott-9-087]                                              2013   Chinese     Lung cancer       PB                360    73        150                 137   360   69    136   155   Sequencing
  Zhao et al[@b9-ott-9-087]                                               2012   Chinese     Gastric cancer    PB                200    41        92                  67    200   36    78    86    Sequencing
  Xu et al[@b16-ott-9-087]                                                2011   Chinese     Cervical cancer   PB                300    83        129                 88    774   128   359   287   Taqman
  Chiu et al[@b11-ott-9-087]                                              2010   Chinese     Oral cancer       NA                97     18        52                  27    100   9     49    42    Sequencing
  Chen et al[@b12-ott-9-087]                                              2010   Chinese     Glioma            HB                664    99        345                 220   669   90    306   273   PCR-LDR
  **rs11730582 (-443C/T)**                                                                                                                                                                          
  Zhu[@b8-ott-9-087]                                                      2013   Chinese     Gastric cancer    HB                106    16        46                  44    106   12    41    53    Sequencing
  Mu et al[@b15-ott-9-087]                                                2013   Chinese     Thyroid cancer    PB                363    119       171                 73    413   62    187   164   Taqman
  Lee et al[@b14-ott-9-087]                                               2013   Chinese     Gastric cancer    HB                146    21        66                  59    128   8     55    65    Sequencing
  Chen et al[@b13-ott-9-087]                                              2013   Chinese     Lung cancer       PB                360    31        165                 164   360   44    163   153   Sequencing
  Zhao et al[@b9-ott-9-087]                                               2012   Chinese     Gastric cancer    PB                200    15        94                  91    200   22    93    85    Sequencing
  Xu et al[@b16-ott-9-087]                                                2011   Chinese     Cervical cancer   PB                300    24        49                  227   774   106   334   334   Taqman
  Chiu et al[@b11-ott-9-087]                                              2010   Chinese     Oral cancer       NA                97     9         41                  47    100   17    50    33    Sequencing
  Chen et al[@b12-ott-9-087]                                              2010   Chinese     Glioma            HB                667    69        299                 299   672   77    311   284   PCR-LDR
  Shin et al[@b10-ott-9-087],[\*](#tfn1-ott-9-087){ref-type="table-fn"}   2007   Korean      Liver cancer      HB                NA     NA        NA                  NA    NA    NA    NA    NA    Taqman

**Note:**

Study with only allele information.

**Abbreviations:** PB, population-based; HB, hospital-based; W, wild-type allele; M, mutant-type allele; NA, not applicable; PCR-LDR, polymerase chain reaction/ligase detection reaction.

###### 

Meta-analysis results of the association between *OPN* rs17524488 (-156-/G) polymorphism and cancer risk

  Genetic model            Group/subgroup   Studies (n)   Heterogeneity test   Statistical model   Test for overall effect                           
  ------------------------ ---------------- ------------- -------------------- ------------------- ------------------------- ----------------------- -----------
  GG vs (-/-)              Overall          7             65.90                0.007               R                         **1.40 (1.03--1.91)**   **0.033**
                           PB               4             79.30                0.002               R                         1.29 (0.81--2.05)       0.290
                           HB               2             0.00                 0.973               F                         **1.37 (1.01--1.86)**   **0.044**
                           Sequencing       4             12.10                0.332               F                         **1.41 (1.07--1.87)**   **0.016**
                           Taqman           2             92.90                \<0.001             R                         1.25 (0.45--3.52)       0.668
  (-/G) vs (-/-)           Overall          7             31.40                0.188               F                         **1.22 (1.07--1.40)**   **0.002**
                           PB               4             46.10                0.135               F                         1.13 (0.95--1.34)       0.163
                           HB               2             0.00                 0.376               F                         **1.34 (1.08--1.66)**   **0.008**
                           Sequencing       4             0.00                 0.670               F                         **1.32 (1.06--1.65)**   **0.012**
                           Taqman           2             56.60                0.129               F                         0.99 (0.79--1.25)       0.964
  G allele vs (-) allele   Overall          7             66.00                0.007               R                         **1.21 (1.04--1.40)**   **0.016**
                           PB               4             79.80                0.002               R                         1.16 (0.91--1.48)       0.222
                           HB               2             0.00                 0.787               F                         **1.20 (1.04--1.39)**   **0.011**
                           Sequencing       4             0.00                 0.432               F                         **1.23 (1.07--1.42)**   **0.004**
                           Taqman           2             93.00                \<0.001             R                         1.13 (0.67--1.90)       0.655

**Note:** Significant results are marked in bold.

**Abbreviations:** OPN, osteopontin; R, random-effect model; F, fixed-effect model; PB, population-based; HB, hospital-based; OR, odds ratio; CI, confidence interval; *P*~het~, *P*-value for heterogeneity test.

###### 

Meta-analysis results of the association between *OPN* rs11730582 (-443C/T) polymorphism and cancer risk

  Genetic model          Group/subgroup   N   Heterogeneity test   Statistical model   Test for overall effect                        
  ---------------------- ---------------- --- -------------------- ------------------- ------------------------- -------------------- -------
  CC vs TT               Overall          8   91.70                \<0.001             R                         0.98 (0.49--1.97)    0.964
                         PB               4   95.90                \<0.001             R                         0.89 (0.25--3.11)    0.852
                         HB               3   72.30                0.027               R                         1.45 (0.68--3.09)    0.333
                         Sequencing       5   71.70                0.007               R                         0.92 (0.49--1.73)    0.787
                         Taqman           2   98.40                \<0.001             R                         1.20 (0.10--14.78)   0.886
  CT vs TT               Overall          8   92.60                \<0.001             R                         0.88 (0.54--1.43)    0.610
                         PB               4   96.50                \<0.001             R                         0.79 (0.31--2.02)    0.627
                         HB               3   29.20                0.243               F                         1.01 (0.83--1.23)    0.925
                         Sequencing       5   28.30                0.233               F                         0.98 (0.81--1.20)    0.863
                         Taqman           2   98.80                \<0.001             R                         0.67 (0.07--6.06)    0.718
  C allele vs T allele   Overall          9   94.40                \<0.001             R                         0.92 (0.64--1.33)    0.665
                         PB               4   96.70                \<0.001             R                         0.87 (0.40--1.87)    0.715
                         HB               4   72.80                0.012               R                         1.06 (0.80--1.39)    0.683
                         Sequencing       5   73.20                0.005               R                         0.97 (0.73--1.29)    0.860
                         Taqman           3   98.40                \<0.001             R                         0.84 (0.28--2.54)    0.756

**Abbreviations:** OPN, osteopontin; R, random-effect model; F, fixed-effect model; PB, population-based; HB, hospital-based; OR, odds ratio; CI, confidence interval; *P*~het~, *P*-value for heterogeneity test.

###### 

Results of publication bias test

  Polymorphism                 Compared genotype        Begg's test   Egger's test           
  ---------------------------- ------------------------ ------------- -------------- ------- -------
  *OPN* rs17524488 (-156-/G)   GG vs (-/-)              0.45          0.652          0.53    0.620
                               (-/G) vs (-/-)           −0.45         0.652          0.02    0.986
                               G allele vs (-) allele   0.45          0.652          0.47    0.656
  *OPN* rs11730582 (-443C/T)   CC vs TT                 0.00          1.000          −0.23   0.823
                               CT vs TT                 0.00          1.000          0.10    0.924
                               C allele vs T allele     −0.42         0.677          −0.22   0.829

**Abbreviation:** OPN, osteopontin.
